|
Administration
Should be taken with food.
|
|
Contraindications
Hypersensitivity, history of sudden death or congenital prolongation of QT interval, history of cardiac arrhythmias, bradycardia, CHF with reduced left ventricle ejection fraction, electrolyte disturbances (e.g. hypokalaemia, hypomagnesemia). Concomitant use with strong CYP3A4 inducers, and with drugs known to prolong QT interval.
|
|
Special Precautions
Severe renal and hepatic impairment. Children. Pregnancy and lactation. Not indicated for the prevention and treatment of severe or complicated malaria. Patient Counselling This drug may cause dizziness, and fatigue, if affected, do not drive or operate machinery. Monitoring Parameters Monitor adequate food consumption during treatment.
|
|
Adverse Reactions
Blood and lymphatic system disorders: Anaemia, splenomegaly.
Cardiac disorders: Palpitations, QT prolongation.
Gastrointestinal disorders: Abdominal pain, nausea, vomiting, diarrhoea.
General disorders and administration site conditions: Asthenia, fatigue, fever, malaise.
Hepatobiliary disorders: Hepatomegaly.
Infections and infestations: Malaria.
Investigations: Increased serum AST.
Metabolism and nutrition disorders: Decreased appetite.
Musculoskeletal and connective tissue disorders: Arthralgia, chills, myalgia.
Nervous system disorders: Dizziness, headache, paraesthesia, clonus, gait disturbance vertigo.
Psychiatric disorders: Sleep disorder, insomnia.
Respiratory, thoracic and mediastinal disorders: Cough, rhinitis.
Skin and subcutaneous tissue disorders: Pruritus, rash.
Potentially Fatal: Anaphylaxis. |
|
Drug Interactions
May reduce effectiveness of hormonal contraceptives.
|
|
CIMS Class
|
|
ATC Classification
P01BE02 - artemether ; Belongs to the class of artemisinin and derivative antimalarials.
|
Sign Out
